Plain-English translation of NCT06796907 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new cancer medication called Mocertatug Rezetecan paired with other established cancer treatments. Researchers want to understand how safe this medication is, how your body processes it, and whether it can help people whose advanced cancers have stopped responding to standard treatments or who cannot tolerate them. The study focuses on specific cancers like endometrial and ovarian cancer.
Many people with advanced cancers eventually develop resistance to single-drug treatments, causing their cancer to return or progress. This trial exists to see if combining this medication with other cancer therapies might work better for patients who have exhausted standard treatment options or cannot tolerate them.
You likely qualify if…
You likely don't qualify if…
You would receive the new medication Mocertatug Rezetecan in combination with one or more standard cancer drugs, depending on which study group you join (for example, endometrial cancer patients may receive it with , while ovarian cancer patients may receive it with or without ). You would attend regular clinic visits for physical exams, blood tests, imaging scans, and safety monitoring. The study involves approximately 305 participants total and is still recruiting patients.
AI-generated summary from trial data · Oct 4, 2026 · Not medical advice
United States